- Home
- PBHC vs XFOR Comparison
PBHC vs XFOR Comparison
Compare PBHC & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBHC
- XFOR
- Stock Information
- Founded
- PBHC 1859
- XFOR 2014
- Country
- PBHC United States
- XFOR United States
- Employees
- PBHC N/A
- XFOR N/A
- Industry
- PBHC Major Banks
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBHC Finance
- XFOR Health Care
- Exchange
- PBHC Nasdaq
- XFOR Nasdaq
- Market Cap
- PBHC 92.9M
- XFOR 84.3M
- IPO Year
- PBHC N/A
- XFOR N/A
- Fundamental
- Price
- PBHC $15.14
- XFOR $3.78
- Analyst Decision
- PBHC
- XFOR Strong Buy
- Analyst Count
- PBHC 0
- XFOR 3
- Target Price
- PBHC N/A
- XFOR $34.17
- AVG Volume (30 Days)
- PBHC 6.2K
- XFOR 1.6M
- Earning Date
- PBHC 10-31-2025
- XFOR 11-07-2025
- Dividend Yield
- PBHC 2.64%
- XFOR N/A
- EPS Growth
- PBHC N/A
- XFOR N/A
- EPS
- PBHC 0.28
- XFOR N/A
- Revenue
- PBHC $39,015,000.00
- XFOR $32,774,000.00
- Revenue This Year
- PBHC N/A
- XFOR $1,307.51
- Revenue Next Year
- PBHC N/A
- XFOR N/A
- P/E Ratio
- PBHC $53.94
- XFOR N/A
- Revenue Growth
- PBHC N/A
- XFOR 5721.31
- 52 Week Low
- PBHC $13.55
- XFOR $1.35
- 52 Week High
- PBHC $18.53
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- PBHC 50.29
- XFOR 61.15
- Support Level
- PBHC $14.65
- XFOR $2.96
- Resistance Level
- PBHC $15.20
- XFOR $4.54
- Average True Range (ATR)
- PBHC 0.18
- XFOR 0.26
- MACD
- PBHC -0.04
- XFOR 0.07
- Stochastic Oscillator
- PBHC 82.44
- XFOR 55.17
About PBHC Pathfinder Bancorp Inc. (MD)
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.